Business
Verastem Oncology to Present at Jefferies Healthcare Conference
Verastem Oncology to Present at Jefferies Healthcare Conference
About this update from Verastem, Inc.
[{"type":"text","content":" BOSTON--(BUSINESS WIRE)--\nVerastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:10 am ET in New York.\n\n\nA live webcast of the fireside chat can be accessed under “Events & Presentations” on the Company’s website at www.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation.\n\n\nAbout Verastem Oncology\n\n\nVerastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI® FAKZYNJA® CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20260527590882/en/\n\nFor Investor and Media Inquiries:\nJulissa Viana\nSenior Vice President, Corporate Communications,\nInvestor Relations & Patient Advocacy\[email protected] or\[email protected]\n\n\nSource: Verastem Oncology","length":4330,"tagName":"div"}]